Pan-Salmonella-without-Alum (Full dose) vaccine

Phase 1Vaccine

Pan-Salmonella-without-Alum (Full dose) vaccine is one of 5 therapeutic programs targeting Infections. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

InfectionsRecruiting

InfectionsPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Infections

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Temocillin

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

Pentaglobin

MMedical University of Vienna

Phase 2

1 4

Pan-Salmonella-without-Alum (Full dose) vaccine

GSK

Phase 1

1 5

HLA-Matched Vsts

BBaylor College of Medicine

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Infections

NCT07663032

Clinical

Trials by Indication[1]

Infections1 trial

A Phase 1, Randomized, Controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GVGH Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Adults 18 to 45 Years of Age in Africa

Recruiting· GSK logo

GSK·Phase 1·NCT07663032·196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pan-Salmonella-without-Alum (Full dose) vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pan-Salmonella-without-Alum (Full dose) vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine
Highest Phase: Phase 1[1]
Company: GSK

Pan-Salmonella-without-Alum (Full dose) vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Infections1 trial

References

Drug Info

Quick Facts

Related News